Therefore, our results indicated that apatinib might exert its inhibitory effects on NSCLC by targeting VEGFR2/STAT3/PD-L1 signaling in both NSCLC cells and tumor derived macrophages and partially restoring theactivation of T cells. The gene discussed is STAT3; the disease is neoplasm.